The manuscripts contained in this special issue of Palliative Medicine are the reports of systematic reviews first presented on 8-9 February 2010 during the 5th Bristol Opioid Conference. The Conference is one of the modules of the Bristol MSc in Palliative Medicine run by Professor Karen Forbes of the Department of Palliative Medicine at the University of Bristol. The speakers and content of the 2 days are chosen with the aim of the MSc in mind, i.e. providing a sound scientific basis for the clinical use of opioids in the management of pain. The programme for each Conference brings together basic laboratory-based scientists with clinical researchers and clinicians and topics cover aspects of the pharmacology, neurophysiology, psychopharmacology and clinical perspective of opioid use. The biennial Conference has highlighted the fact that whilst there have been great advances in understanding both the molecular pharmacology of opioid analgesics and also the basic cellular mechanisms involved in cancer pain, this has not yet led to the introduction of new drugs targeted at these processes. The most important advances in the clinical therapeutics of cancer pain have been in the development of new formulations of old drugs (modified release oral formulations, transdermal, and transmucosal). This has made these drugs much more flexible in clinical use but has also resulted in different ways of using them and controversies about what constitutes best practice.
Over the 8 years of Opioid Conferences, increasing emphasis has been placed on reporting the 'evidence' for opioids during the conference, reflecting the appetite for evidence-based healthcare in the wider healthcare community. It seemed appropriate therefore that the 5th Conference was the vehicle for the initial presentation of the European Palliative Care Research Collaborative (EPCRC) systematic reviews and guidelines for the use of opioids in the management of cancer pain. The aim has been to update the EAPC (European Association for Palliative Care) Recommendations on opioids in cancer pain. The conference was held in collaboration with the Research Network of the EAPC and the EPCRC and during it, the decision was made to have this special issue of Palliative Medicine exclusively devoted to the reporting of the reviews.
A great deal of time and effort has been put into these manuscripts; they are the result of exhaustive literature searches, painstaking data extraction and assessment of methodological quality as well as the time and effort provided by the reviewers who gave us helpful comments and guidance on improving their quality. It seems a great pity then that so many of them report difficulties with finding suitable studies for inclusion and are therefore unable to provide robust evidence-based (as opposed to expert opinion-based) recommendations. Laugsand and colleagues, for example, tried to find studies on the management of opioid-induced nausea and vomiting; a side effect likely to impact on quality of life of the many patients requiring opioids for the management of cancer pain and were unable to retrieve any randomised trials. Klepstad and colleagues point out that their recommendation for oral opioid dose titration rests upon data from only 36 patients in one randomized trial. The relatively recent practice of switching opioids to improve analgesia or reduce side-effects is not supported by a single randomized controlled trial. The place of spinal opioids in cancer pain management remains unclear because of the poor quality of the evidence. It was this particular question, the role of spinal opioids, which prompted the first EAPC guidelines on opioids in cancer pain. What is shocking when all of these reviews are considered together is the magnitude of the task which remains to fill the gaps in evidence. Symptom control and particularly the relief of pain is one of the core activities of palliative care, yet we can still only draw attention to the paucity of high-quality evidence available to support our clinical practice. These reviews must surely represent a 'call to arms' for the palliative medicine research community? They highlight the many areas where we cannot be confident that our practice is 'best practice' because it is not evidence-based. The data make clear what we do not know and where future efforts should be aimed. What are we waiting for?
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